Contract research company SNBL has backed an $18m series A round for Wave Life Sciences, which focuses on engineering precise molecular structures for drug development.
US-based biotechnology company Wave Life Sciences closed an $18m series A round yesterday backed by contract research company SNBL, and co-led by RA Capital Management and Kagoshima Shinsangyo Sosei Investment.
Wave has developed a drug discovery platform that provides programmable control over the molecular structure of a drug during synthesis, enabling it to manufacture therapeutics with enhanced pharmaceutical properties.
The company expects to use the technology to design next-generation drugs that will significantly improve treatment of a wide range…
